Sera Prognostics Showcases Innovations at Health Conference
Sera Prognostics Inc., known as The Pregnancy Company®, is dedicated to enhancing maternal and neonatal health by offering innovative biomarker information to both healthcare providers and expectant mothers. The company is slated to present at the TD Cowen 45th Annual Health Care Conference where their President and CEO, Zhenya Lindgardt, will participate in an insightful fireside chat.
Event Details
This presentation will occur on a Wednesday morning, providing an excellent platform for discussion on the strides made in pregnancy-related health diagnostics. The session, ranging from early to late morning, will allow healthcare professionals and stakeholders to gain a contemporary view of Sera's latest achievements and future goals.
A Stream of Information
Following the presentation, a live webcast will be accessible for those who wish to engage with the content remotely. This feature reflects Sera Prognostics’ commitment to transparency and accessibility, ensuring that both medical stakeholders and the public remain informed about advancements impacting pregnancy care.
About Sera Prognostics, Inc.
Sera Prognostics aims to transform the landscape of pregnancy care through its cutting-edge diagnostic processes. Their focus is not only on evaluating risks related to preterm birth but also on providing actionable insights that lead to better clinical decisions. The company’s renowned PreTRM® Test exemplifies their dedication, offering physicians critical data about preterm birth risk that can lead to timely interventions for those most at risk.
About Preterm Birth
Every year, many infants are born prematurely, defined as births that occur before 37 weeks of gestation. Such early arrivals can lead to severe health complications and even heightened healthcare costs throughout the lives of these children. The significant annual expenditure linked to managing preterm complications highlights the dire need for effective risk assessment and intervention strategies.
The PreTRM® Test
The innovative PreTRM® Test stands out as the only commercially available blood test thoroughly validated for assessing the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. By measuring specific proteins, this test aids healthcare providers in identifying at-risk individuals during critical periods of pregnancy, allowing for tailored healthcare strategies aimed at reducing the risks of complications.
The Importance of Innovation in Healthcare
As the landscape of healthcare evolves, it becomes increasingly vital for companies like Sera Prognostics to lead in offering innovative solutions that address pressing maternal and neonatal health issues. Their dedication to precision medicine not only aligns with current healthcare demand but also sets a benchmark for future advancements in diagnostic testing.
Frequently Asked Questions
What is the focus of Sera Prognostics?
Sera Prognostics focuses on improving maternal and neonatal health through innovative pregnancy biomarker information.
What is the PreTRM® Test?
The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in pregnant women.
When will Sera Prognostics present at the conference?
Sera Prognostics will present at the TD Cowen 45th Annual Health Care Conference on a Wednesday morning in March.
Why is preterm birth a concern?
Preterm birth poses significant health risks to newborns and can lead to long-term medical complications, impacting the child's health and associated costs.
How can healthcare providers use the PreTRM® Test?
Healthcare providers can use the PreTRM® Test to identify pregnant women at higher risk of preterm birth, enabling personalized care and timely interventions.
